从系统性硬化症前期的灰色地带到极早期疾病与不可逆组织损伤:为未来预防试验定义高危患者的挑战
本文为观点文章,探讨预防试验能否应用于系统性硬化症(SSc)。与1型糖尿病和类风湿关节炎已有较明确的疾病前期定义不同,SSc尚无预SSc的共识定义;需集体起草共识框架以识别可能处于预SSc阶段的患者,为早期识别、风险分层和及时干预提供基础。
要点
- SSc是死亡率最高的系统性自身免疫风湿病,目前缺乏预SSc的共识定义。
- 需集体起草共识框架,识别与其他结缔组织病重叠但可能处于预SSc阶段的患者。
- 借鉴1型糖尿病和类风湿关节炎的转变,针对SSc高危人群的策略有望预防关键症状、促进长期缓解并降低病死率。
核心结论
- 预SSc尚无共识定义,需集体起草共识框架以识别可能处于预SSc阶段的患者,为早期识别、风险分层和及时干预提供基础。
研究设计与样本
- 本文为观点文章,旨在探讨预防试验能否应用于系统性硬化症(SSc)。
主要发现
- 与1型糖尿病和类风湿关节炎已有较明确的疾病前期定义不同,SSc尚无预SSc的共识定义。
- 存在与其他系统性自身免疫风湿病/结缔组织病共有的体征和症状,但可能识别处于预SSc阶段的患者,需集体起草共识框架。
临床怎么用
- 共识框架可为预SSc患者的早期识别、风险分层和及时干预提供基础。
- 借鉴1型糖尿病和类风湿关节炎的范式转变,针对SSc高危人群的策略可能促进预防关键体征和症状、长期缓解及降低发病率与病死率的新方法开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This viewpoint aims to explore whether precondition trials could be applied in systemic sclerosis (SSc)-the systemic autoimmune rheumatic disease (SARD) associated with the highest mortality and substantial morbidity. In contrast to type 1 diabetes and rheumatoid arthritis (RA), where predisease states have been more clearly defined, a consensus definition for pre-SSc is still lacking. A consensus framework for patients with signs and symptoms also common to other SARDs/connective tissue diseases, but that potentially identify a patient at a pre-SSc stage, needs to be collectively drafted. Such a framework would provide the basis for earlier recognition, risk stratification, and ultimately, timely intervention in pre-SSc. Considering the paradigm shift already achieved in type 1 diabetes and RA, a similar strategy targeting patients at risk of SSc could foster the development of innovative approaches to SSc management-preventing the onset of key SSc-related signs and symptoms, promoting long-term remission, and reducing SSc-related morbidity and mortality.
引用
- Lescoat A, Allanore Y, Del Galdo F, et al. From the grey area of pre-systemic sclerosis to very early disease and irreversible tissue damage: the challenge of defining at-risk patients for future preventive trials in systemic sclerosis. Ann Rheum Dis. 2025. PMID: 41444065. doi:10.1016/j.ard.2025.11.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。